Source: Tech – South China Morning PostBiotech firm Ascletis Pharma said ASC47, its muscle-preserving weight loss drug candidate, could boost the efficacy of the popular anti-obesity medication semaglutide by 56.2 per cent, as Chinese drug makers eye a growing share of this lucrative market.
That finding came from a trial that Ascletis conducted in the US for 28 participants with obesity, which aimed to assess the drug candidate’s safety and ideal dose, according to the company’s statement on Monday. The treatment duration was four…Read More